PRIMABS-Dx for BH3 mimetics (e.g., venetoclax)

About Eutropics Pharmaceuticals

Eutropics Pharmaceuticals, founded in 2008 and based in Cambridge, USA, is pioneering a novel class of functional companion diagnostics (CDx) in oncology. The company's core technology, the PRIMABS-Dx platform, uses conformation-specific antibodies to detect protein-protein interactions (PPIs) within the BCL-2 family, a key regulator of apoptosis. This approach measures 'mitochondrial priming,' a functional state of a tumor cell that predicts its vulnerability to drugs like venetoclax, offering a solution beyond genetic markers. Eutropics is initially targeting hematologic malignancies like AML, where a lack of predictive biomarkers leads to high first-line treatment failure rates.

Therapeutic Areas